AFN-1252 | CAS#620175-39-5 | FabI inhibitor

MedKoo Cat#: 526918 | Name: AFN-1252

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AFN-1252, also known as AFN-12520000; API-1252; Debio-1452, is FASII Inhibitor which is potentially for the treatment of acute bacterial skin. AFN-1252 exhibits typical MIC(90) values of ≤0·015 μg/ml against diverse clinical isolates of S. aureus, oral absorption, long elimination half-live and efficacy in animal models. AFN-1252 efficiently blocked daptomycin-induced phospholipid decoy production, even in the case of isolates resistant to AFN-1252, which prevented the inactivation of daptomycin and resulted in sustained bacterial killing. In turn, daptomycin prevented the fatty acid-dependent emergence of AFN-1252-resistant isolates in vitro

Chemical Structure

AFN-1252

CAS#620175-39-5 (free base)

Theoretical Analysis

MedKoo Cat#: 526918

Name: AFN-1252

CAS#: 620175-39-5 (free base)

Chemical Formula: C22H21N3O3

Exact Mass: 375.1583

Molecular Weight: 375.43

Elemental Analysis: C, 70.38; H, 5.64; N, 11.19; O, 12.78

Price and Availability

Size	Price	Availability
5mg	USD 110.00	Ready to ship
10mg	USD 190.00	Ready to ship
25mg	USD 350.00	Ready to ship
50mg	USD 550.00	Ready to ship
100mg	USD 950.00	Ready to ship
200mg	USD 1,650.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1047981-31-6 (tosylate) 620175-39-5 (free base) 1047981-30-5 (tosylate hydrate)

Synonym

AFN-1252; AFN 1252; AFN1252; API-1252; API1252; API 1252; AFN12520000; AFN 12520000; AFN12520000; Debio1452; Debio 1452; Debio1452;

IUPAC/Chemical Name

(E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide

InChi Key

QXTWSUQCXCWEHF-JXMROGBWSA-N

InChi Code

InChI=1S/C22H21N3O3/c1-14-17-5-3-4-6-18(17)28-19(14)13-25(2)21(27)10-7-15-11-16-8-9-20(26)24-22(16)23-12-15/h3-7,10-12H,8-9,13H2,1-2H3,(H,23,24,26)/b10-7+

SMILES Code

O=C(N(C)CC1=C(C)C2=CC=CC=C2O1)/C=C/C3=CC(CC4)=C(N=C3)NC4=O

Appearance

White to off-white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#T8Z01C18

QC Data

View QC data: current batch, Lot#T8Z01C18

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

AFN-1252 (Debio 1452) is a potent inhibitor of enoyl-acyl carrier protein reductase (FabI).

In vitro activity:

The effect of increasing concentrations of AFN-1252 on the growth rate of L. monocytogenes in planktonic culture was measured to determine the contribution of LmFabI versus LmFabK1 to fatty acid synthesis and growth. AFN-1252 caused the cessation of cell growth after 1 to 2 cellular doublings in bacterial genes encoding a single, essential FabI. In contrast, increasing concentrations of AFN-1252 slowed but did not stop the growth of L. monocytogenes (Fig. 3A). Pathway labeling experiments showed that AFN-1252 selectively inhibited lipid synthesis, with minimal perturbation to protein, DNA, and RNA synthesis (Fig. 3B). Therefore, the reduction of growth rate by AFN-1252 was attributed to on-target inhibition of LmFabI and fatty acid synthesis. Reference: Infect Immun. 2016 Dec; 84(12): 3597–3607. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116736/

In vivo activity:

The first experiments involved administering a single oral dose of AFN-1252 (100 mg/kg) 2 h after infecting the granuloma pouches and examining the effect of AFN-1252 on pouch-associated CFU within 48 h of dosing (Fig. 3A). Little change in the bacterial load was detected within the first 12 h of AFN-1252 treatment, but between 24 and 48 h, there was a 3.0-log10 reduction in the mean CFU/ml of pouch fluid collected from AFN-1252-treated mice compared to untreated mice (Fig. 3A). Wood46 counts in untreated pouch fluid increased to 7.5 log10 CFU/ml at 24 h, while bacterial counts in AFN-1252-treated pouches dropped to 4.4 log10 CFU/ml in 24 h. When 100 mg/kg of AFN-1252 was orally administered once a day for 3 days (+2, +26, and +50 h), AFN-1252 reduced 72-hour S. aureus CFU counts in the pouches of treated animals by 5 orders of magnitude compared to untreated controls, which was near the detection limit for this model (Fig. 3B). These data illustrate that orally administered AFN-1252 can reach therapeutic levels in the mouse granuloma pouch and effectively resolve the S. aureus infection associated with the pouch fluid. Reference: Antimicrob Agents Chemother. 2013 May; 57(5): 2182–2190. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3632907/

	Solvent	mg/mL	mM
Solubility
	DMSO	5.8	15.45

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 375.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Yao J, Ericson ME, Frank MW, Rock CO. Enoyl-Acyl Carrier Protein Reductase I (FabI) Is Essential for the Intracellular Growth of Listeria monocytogenes. Infect Immun. 2016 Nov 18;84(12):3597-3607. doi: 10.1128/IAI.00647-16. PMID: 27736774; PMCID: PMC5116736. 2. Flamm RK, Rhomberg PR, Kaplan N, Jones RN, Farrell DJ. Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. Antimicrob Agents Chemother. 2015 May;59(5):2583-7. doi: 10.1128/AAC.05119-14. Epub 2015 Feb 17. PMID: 25691627; PMCID: PMC4394798. 3. Parsons JB, Kukula M, Jackson P, Pulse M, Simecka JW, Valtierra D, Weiss WJ, Kaplan N, Rock CO. Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252. Antimicrob Agents Chemother. 2013 May;57(5):2182-90. doi: 10.1128/AAC.02307-12. Epub 2013 Mar 4. PMID: 23459481; PMCID: PMC3632907. 4. Banevicius MA, Kaplan N, Hafkin B, Nicolau DP. Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model. J Chemother. 2013 Feb;25(1):26-31. doi: 10.1179/1973947812Y.0000000061. PMID: 23433441; PMCID: PMC3558988.

In vitro protocol:

In vivo protocol:

1. Parsons JB, Kukula M, Jackson P, Pulse M, Simecka JW, Valtierra D, Weiss WJ, Kaplan N, Rock CO. Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252. Antimicrob Agents Chemother. 2013 May;57(5):2182-90. doi: 10.1128/AAC.02307-12. Epub 2013 Mar 4. PMID: 23459481; PMCID: PMC3632907. 2. Banevicius MA, Kaplan N, Hafkin B, Nicolau DP. Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model. J Chemother. 2013 Feb;25(1):26-31. doi: 10.1179/1973947812Y.0000000061. PMID: 23433441; PMCID: PMC3558988.

1: Zhou B, Pathania A, Pant D, Halpern D, Gaudu P, Trieu-Cuot P, Dias-Leao A, Pagot C, Solgadi A, Gruss A, Gloux K. Prophages divert Staphylococcus aureus defenses against host lipids. J Lipid Res. 2024 Dec;65(12):100693. doi: 10.1016/j.jlr.2024.100693. Epub 2024 Nov 5. PMID: 39505263; PMCID: PMC11721228. 2: Jankov M, Léguillier V, Gašić U, Anba-Mondoloni J, Ristivojević MK, Radoičić A, Dimkić I, Ristivojević P, Vidic J. Antibacterial Activities of Agaricus bisporus Extracts and Their Synergistic Effects with the Antistaphylococcal Drug AFN-1252. Foods. 2024 May 30;13(11):1715. doi: 10.3390/foods13111715. PMID: 38890946; PMCID: PMC11172267. 3: Pruitt EL, Zhang R, Ross DH, Ashford NK, Chen X, Alonzo F 3rd, Bush MF, Werth BJ, Xu L. Elucidating the impact of bacterial lipases, human serum albumin, and FASII inhibition on the utilization of exogenous fatty acids by Staphylococcus aureus. mSphere. 2023 Dec 20;8(6):e0036823. doi: 10.1128/msphere.00368-23. Epub 2023 Nov 28. PMID: 38014966; PMCID: PMC10732024. 4: Pruitt EL, Zhang R, Ross DH, Ashford NK, Chen X, Alonzo F 3rd, Bush MF, Werth BJ, Xu L. Elucidating the Impact of Bacterial Lipases, Human Serum Albumin, and FASII Inhibition on the Utilization of Exogenous Fatty Acids by Staphylococcus aureus. bioRxiv [Preprint]. 2023 Jun 30:2023.06.29.547085. doi: 10.1101/2023.06.29.547085. Update in: mSphere. 2023 Dec 20;8(6):e0036823. doi: 10.1128/msphere.00368-23. PMID: 37425828; PMCID: PMC10327171. 5: Maltarollo VG, Shevchenko E, Lima IDM, Cino EA, Ferreira GM, Poso A, Kronenberger T. Do Go Chasing Waterfalls: Enoyl Reductase (FabI) in Complex with Inhibitors Stabilizes the Tetrameric Structure and Opens Water Channels. J Chem Inf Model. 2022 Nov 28;62(22):5746-5761. doi: 10.1021/acs.jcim.2c01178. Epub 2022 Nov 7. PMID: 36343333. 6: Yang X, Wang G, Ye ZS. Palladium-catalyzed nucleomethylation of alkynes for synthesis of methylated heteroaromatic compounds. Chem Sci. 2022 Aug 18;13(34):10095-10102. doi: 10.1039/d2sc03294e. PMID: 36128232; PMCID: PMC9430495. 7: Rao NK, Nataraj V, Ravi M, Panchariya L, Palai K, Talapati SR, Lakshminarasimhan A, Ramachandra M, Antony T. Ternary complex formation of AFN-1252 with Acinetobacter baumannii FabI and NADH: Crystallographic and biochemical studies. Chem Biol Drug Des. 2020 Aug;96(2):704-713. doi: 10.1111/cbdd.13686. Epub 2020 Apr 22. PMID: 32227402. 8: Kénanian G, Morvan C, Weckel A, Pathania A, Anba-Mondoloni J, Halpern D, Gaillard M, Solgadi A, Dupont L, Henry C, Poyart C, Fouet A, Lamberet G, Gloux K, Gruss A. Permissive Fatty Acid Incorporation Promotes Staphylococcal Adaptation to FASII Antibiotics in Host Environments. Cell Rep. 2019 Dec 17;29(12):3974-3982.e4. doi: 10.1016/j.celrep.2019.11.071. PMID: 31851927. 9: Pee CJE, Pader V, Ledger EVK, Edwards AM. A FASII Inhibitor Prevents Staphylococcal Evasion of Daptomycin by Inhibiting Phospholipid Decoy Production. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02105-18. doi: 10.1128/AAC.02105-18. PMID: 30718253; PMCID: PMC6496159. 10: Menetrey A, Janin A, Pullman J, Overcash JS, Haouala A, Leylavergne F, Turbe L, Wittke F, Nicolas-Métral V. Bone and Joint Tissue Penetration of the Staphylococcus-Selective Antibiotic Afabicin in Patients Undergoing Elective Hip Replacement Surgery. Antimicrob Agents Chemother. 2019 Feb 26;63(3):e01669-18. doi: 10.1128/AAC.01669-18. PMID: 30559136; PMCID: PMC6395911. 11: Yao J, Rock CO. Therapeutic Targets in Chlamydial Fatty Acid and Phospholipid Synthesis. Front Microbiol. 2018 Sep 25;9:2291. doi: 10.3389/fmicb.2018.02291. PMID: 30319589; PMCID: PMC6167442. 12: Morvan C, Halpern D, Kénanian G, Pathania A, Anba-Mondoloni J, Lamberet G, Gruss A, Gloux K. The Staphylococcus aureus FASII bypass escape route from FASII inhibitors. Biochimie. 2017 Oct;141:40-46. doi: 10.1016/j.biochi.2017.07.004. Epub 2017 Jul 17. PMID: 28728970. 13: Yao J, Ericson ME, Frank MW, Rock CO. Enoyl-Acyl Carrier Protein Reductase I (FabI) Is Essential for the Intracellular Growth of Listeria monocytogenes. Infect Immun. 2016 Nov 18;84(12):3597-3607. doi: 10.1128/IAI.00647-16. PMID: 27736774; PMCID: PMC5116736. 14: Hafkin B, Kaplan N, Murphy B. Efficacy and Safety of AFN-1252, the First Staphylococcus-Specific Antibacterial Agent, in the Treatment of Acute Bacterial Skin and Skin Structure Infections, Including Those in Patients with Significant Comorbidities. Antimicrob Agents Chemother. 2015 Dec 28;60(3):1695-701. doi: 10.1128/AAC.01741-15. PMID: 26711777; PMCID: PMC4775962. 15: Yao J, Bruhn DF, Frank MW, Lee RE, Rock CO. Activation of Exogenous Fatty Acids to Acyl-Acyl Carrier Protein Cannot Bypass FabI Inhibition in Neisseria. J Biol Chem. 2016 Jan 1;291(1):171-81. doi: 10.1074/jbc.M115.699462. Epub 2015 Nov 13. PMID: 26567338; PMCID: PMC4697154. 16: Hunt T, Kaplan N, Hafkin B. Safety, tolerability and pharmacokinetics of multiple oral doses of AFN-1252 administered as immediate release (IR) tablets in healthy subjects. J Chemother. 2016 Jun;28(3):164-71. doi: 10.1179/1973947815Y.0000000075. Epub 2016 May 13. PMID: 26431470. 17: Hafkin B, Kaplan N, Hunt TL. Safety, tolerability and pharmacokinetics of AFN-1252 administered as immediate release tablets in healthy subjects. Future Microbiol. 2015;10(11):1805-13. doi: 10.2217/fmb.15.101. Epub 2015 Sep 11. PMID: 26357940. 18: Flamm RK, Rhomberg PR, Kaplan N, Jones RN, Farrell DJ. Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. Antimicrob Agents Chemother. 2015 May;59(5):2583-7. doi: 10.1128/AAC.05119-14. Epub 2015 Feb 17. PMID: 25691627; PMCID: PMC4394798. 19: Rao KN, Lakshminarasimhan A, Joseph S, Lekshmi SU, Lau MS, Takhi M, Sreenivas K, Nathan S, Yusof R, Abd Rahman N, Ramachandra M, Antony T, Subramanya H. AFN-1252 is a potent inhibitor of enoyl-ACP reductase from Burkholderia pseudomallei--Crystal structure, mode of action, and biological activity. Protein Sci. 2015 May;24(5):832-40. doi: 10.1002/pro.2655. Epub 2015 Apr 2. PMID: 25644789; PMCID: PMC4420531. 20: Yao J, Abdelrahman YM, Robertson RM, Cox JV, Belland RJ, White SW, Rock CO. Type II fatty acid synthesis is essential for the replication of Chlamydia trachomatis. J Biol Chem. 2014 Aug 8;289(32):22365-76. doi: 10.1074/jbc.M114.584185. Epub 2014 Jun 23. PMID: 24958721; PMCID: PMC4139244.